General Information of Drug (ID: DMR6YH3)

Drug Name
GLP-1 Drug Info
Synonyms
Glucagon-like peptide 1; Glucagon-like-peptide-1; Glucagon-like peptide-1; Proglucagon (72-108); Proglucagon (78-107)amide; Glucagon-related peptide I; 89750-14-1; GLP-1 (7-36) amide (human, bovine, guinea pig, mouse,; Oral GLP (diabetes, eligen), Emisphere; GLP-1 (oral tablet, Eligen, diabetes); Glucagon-like peptides (oral, eligen), Emisphere; GLP-1 (oral tablet, Eligen, diabetes), Emisphere; NH2-HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR-CONH2
Indication
Disease Entry ICD 11 Status REF
Diabetic complication 5A2Y Phase 3 [1]
Cross-matching ID
PubChem CID
16135499
CAS Number
CAS 89750-14-1
TTD Drug ID
DMR6YH3

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Semaglutide DMAGFOD Type-2 diabetes 5A11 Approved [2]
Liraglutide DM3FXPS Non-insulin dependent diabetes 5A11 Approved [3]
Exenatide DMYHBKN Inflammation 1A00-CA43.1 Approved [4]
Dulaglutide DMYXBV3 Type-2 diabetes 5A11 Approved [5]
Lixisenatide DM0QJDC Type-2 diabetes 5A11 Approved [6]
Pramlintide DM0EZ9Q Type-1/2 diabetes 5A10-5A11 Approved [3]
Albiglutide DM1JEGF Type-2 diabetes 5A11 Approved [6]
Tirzepatide DMQNMAT Type 2 diabetes 5A11 Approved [7]
Efpeglenatide DMKA2PI Type-2 diabetes 5A11 Phase 3 [8]
Taspoglutide DMPYET9 Type-1 diabetes 5A10 Phase 3 [9]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Glucagon-like peptide 1 receptor (GLP1R) TTVIMDE GLP1R_HUMAN Modulator [2]

References

1 Clinical pipeline report, company report or official report of Emisphere Technologies Inc.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 249).
3 Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
4 Improved glycemic control and reduction of cardiometabolic risk factors in subjects with type 2 diabetes and metabolic syndrome treated with exenatide in a clinical practice setting. Diabetes TechnolTher. 2009 Jun;11(6):353-9.
5 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
6 GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus.Nat Rev Endocrinol.2012 Dec;8(12):728-42.
7 Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes. J Clin Endocrinol Metab. 2021 Jan 23;106(2):388-396.
8 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9 Pharmacokinetic and pharmacodynamic properties of taspoglutide, a once-weekly, human GLP-1 analogue, after single-dose administration in patients with Type 2 diabetes. Diabet Med. 2009 Nov;26(11):1156-64.